Ocugen Inc (OCGN)
$0.63 0.00 (0.00%)
19:59 EST OCGN Stock Quote Delayed 15 Minutes
Previous Close $0.63
Market Cap -
PE Ratio -
Volume (Avg. Vol.)
Day's Range 0.63 - 0.63
52-Week Range 0.24 - 8.62
Dividend & Yield N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
- From InvestorPlace
- From the Web
By David Moadel
A pipeline of treatments for underserved eye conditions like oGVHD makes OCGN stock worth considering as part of your biotech holdings.
Except for a couple of specific investors, Ocugen stock is not one for average people. Instead, look at Bausch Health Companies, which has a very rocky backstory but has managed to turn the corner.
Ocugen stock has an intriguing bull case based on its pipeline. But the nano-cap biotech is as risky as any stock in the space.
OCGN stock makes an attractive speculative case because of the underlying company’s potential to address rare eye diseases. Still, this is an opportunity that only risk-takers with “dumb money” should engage.
With two orphan drug designations and a promising partnership, Ocugen stock makes a good play for speculative investors.
How Ocugen stock came to be makes no sense. Neither does the idea that investors will continue to pour money into this cesspool.
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.
Ocugen (OCGN) news for Wednesday about a massive stock buyback plan for $2 million worth of shares has OCGN stock on the move.